1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chengdu Huasun Technology Group Inc., Ltd. Class A

Chengdu Huasun Technology Group Inc., Ltd. Class A

SSZSE:000790
3.76
CNY
+0.06
(+1.62%)
2.18BMarket Cap
Chengdu Huasun Technology Group Inc., Ltd. Class A
SZSE:000790
(Shenzhen Stock Exchange)

Recent

price

3.76

P/E

ratio

- -

div

yld

0.18%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.8
0.89
0.94
1.07
0.86
0.75
0.93
0.96
1.03
1.21
1.21
1.54
1.48
1.45
1.29
0.87
- -
Revenue per Share
0.02
0.03
0.05
0.08
0.11
-0.06
0.13
0.28
0.05
0.1
0.06
0.09
0.07
0.04
-0.01
-0.51
- -
Basic EPS, GAAP
0.15
0.07
-0.15
-0.02
-0.07
-0.12
0.08
-0.06
0.16
0.1
0.02
-0.29
-0.02
-0.21
-0.12
0.04
- -
Free Cash Flow per Basic Share
0.02
0.03
0.01
0.03
0.05
0.03
0.01
0.01
0.05
0.03
0.01
0.01
0.02
0.03
0.03
0.02
0.01
Dividend per Share
0.75
0.8
0.89
0.95
1.03
0.95
1.08
1.36
1.36
1.43
1.48
1.57
1.6
1.64
1.64
1.15
1.16
Book Value per Share
0.6
0.65
0.74
0.78
0.95
0.88
1.02
1.33
1.32
1.4
1.45
1.44
1.36
1.24
1.18
0.89
0.91
Tangible Book Value per Share
614
617
616
616
617
616
616
616
616
616
625
618
589
691
669
628
623
Basic Weighted Avg Shares
489
552
581
658
528
463
575
591
633
745
759
955
873
1,003
864
545
- -
Sales/Revenue/Turnover
6.09
4.56
8.2
9.22
5.34
0.09
10.76
7.73
5.71
9.21
7.06
9.28
6.27
5.71
4.42
-17.09
- -
Operating Margin (%)
24
24
20
20
22
26
29
24
22
16
15
21
34
35
40
47
- -
Depreciation Expense
12
21
34
50
66
-37
82
172
31
62
38
56
41
28
-7
-320
- -
Net Income, GAAP
23.24
18.55
16.24
13.14
24.65
- -
23.35
23.65
28.04
18.64
15.79
20.92
18.81
- -
359.79
- -
- -
Effective Tax Rate (%)
2.55
3.78
5.8
7.61
12.51
-8.07
14.34
29.05
4.92
8.27
4.94
5.83
4.72
2.76
-0.77
-58.74
- -
Profit Margin (%)
94
182
194
184
252
225
345
556
552
610
652
598
236
-13
-133
-133
-124
Working Capital
- -
- -
- -
- -
- -
- -
- -
11
11
11
- -
24
99
16
80
51
54
LT Debt
461
493
546
585
632
583
666
839
836
881
912
986
1,005
1,076
1,068
707
709
Total Equity
2.17
2.9
4.79
6.94
1.31
- -
10.69
17.93
3.15
7.03
4.36
5.18
2.83
- -
-0.78
- -
- -
Return on Invested Capital (%)
3.26
4.46
6.24
8.06
9.58
- -
11.25
20.05
3.67
7.09
4.17
6.26
4.68
- -
-2.53
- -
- -
Return on Capital (%)
2.9
4.38
6.49
8.85
10.85
-6.15
13.21
22.82
3.72
7.18
4.18
5.88
4.15
2.72
-0.65
-36.8
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
312
326
336
LT Borrowings
38
41
38
LT Finance Leases
13
12
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
624
624
624
Market Capitalization
2,414
2,576
2,177

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
460
471
486
Cash, Cash Equivalents & STI
123
112
120
Accounts Receivable, Net
230
234
227
Inventories
56
60
67
Total Current Liabilities
592
591
610
Payables & Accruals
- -
- -
- -
ST Debt
312
326
336
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.12%
-3.5%
-33.81%
Free Cash Flow
-140.42%
-116.97%
-128.75%
Net Income, GAAP
431.9%
910.95%
4,689.37%
Sales/Revenue/Turnover
3.5%
-3.73%
-36.86%
Total Cash Common Dividend
40.09%
24.03%
-35.73%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
179
279
205
201
864
2025
127
165
- -
88
545
2026
109
124
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
-0.01
-0.02
-0.01
2025
-0.02
-0.06
- -
-0.36
-0.51
2026
- -
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.02
- -
0.03
2025
0.01
0.01
- -
-0.01
0.02
2026
0.01
0.01
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chengdu Huasun Technology Group Inc., Ltd. operates primarily as a pharmaceutical company engaged in the research, development, production, and sale of traditional Chinese medicines, Western medicines, biopharmaceutical products, and health supplements. Its core product portfolio includes Sanqitongshu capsules, nasal relief oral solution, Vitacol oral solution, antipyretic oral solution, national class 1 new drugs, Licatin (iodine [131I] metuximab injection), voriconazole tablets, roxithromycin dispersible tablets, and phenbromalone capsules. The company also operates in related pharmaceutical technical services and consulting along with merchandise and property management consulting. Beyond pharmaceuticals, Chengdu Huasun is involved in the design and construction of steel structure buildings. Founded in 1988 and headquartered in Chengdu, China, the company evolved from the pharmaceutical factory affiliated with Chengdu University of Traditional Chinese Medicine and has been listed on the Shenzhen Stock Exchange since 1998. Recent major developments include the cancellation in mid-2024 of a previously planned acquisition of Sichuan Bohaoda Biotechnology Co., Ltd., which was valued at approximately CNY 1 billion. In 2025, Chengdu Huasun’s flagship product, Sanqitongshu capsules, received national secondary protection status as the first traditional Chinese medicine to do so, underscoring its strategic importance in the company's portfolio. The company is also actively streamlining its operations by reducing non-core construction projects to better allocate resources towards its pharmaceutical business. Financially, the company faced pressures in 2025 with reported declining revenues and net losses compared to previous years. Additionally, its subsidiary Xingrui Pharmaceutical sold a 5.4% stake in Shanghai Lingkai, signaling strategic portfolio adjustments. Chengdu Huasun’s operational footprint is primarily in China, with a focus on pharmaceutical markets targeting both traditional Chinese medicine and Western medicine consumers, as well as biopharmaceutical innovation. The firm is recognized for its significant contributions to pharmaceutical technology innovation, holding numerous awards including the National High-tech Industrialization Ten Year Achievement Award and rankings in national proprietary Chinese medicine industry lists. It maintains control under the umbrella of Yuanhong Technology and Xinghui Group subsidiaries, reflecting a broader corporate structure focused on growth within the pharmaceutical and healthcare sectors. This combination of traditional Chinese medicine expertise, biopharmaceutical innovation, and strategic operational adjustments highlights Chengdu Huasun Technology Group Inc., Ltd.'s positioning as a leading player in China’s pharmaceutical industry with ongoing efforts to optimize its business structure and product offerings.